In conclusion, the convergence of PCSK9 inhibition with anti-PD-1/PD-L1 immunotherapy presents a multifaceted approach to cancer treatment, offering a tapestry of benefits that extend beyond the conventional therapeutic modalities. The gene discussed is PDCD1; the disease is cancer.